This user has not filled out their profile yet.

Will the 'Trump' Stock Market Rally Continue Through 2017?

Posted 1 month.

4 Comments

  • Natalie I Giroux - 16 hours ago

    I think Donald Trump has already done more good than Obama did harm in all the years he was in command.
    Obama is the one who tore down the US of A deliberately and with forethought. He is a Muslim, raised and practising, believes in mohammed and he was determined to do all he harm he could to bring down a great country and prepare it for destruction. The Islamic bible,(the quran )states that muslims (faithful, practising) must "kill the infidel", which is clearly written in their book of practical religion. This has been true thoughout
    history and is no LESS true now. Children of the Islamic faithful are taught hate with mothers' milk. I have some very good friends who were raised in Iran under the Islamic faith, which they are forced to study and adhere to. Now immigrated from Iran, no longer practice nor adhere to the god of allah, and have nothing good to say of Islamic practice of jihad, I question why the Islamic faith must before forced upon people. If it was good and allah a real god, they would Not have to force people to accept this faith. I feel sorry for these people, that they do not know love, happiness, joy of life, but only hate, anger and killing of anyone who does not follow their allah. If this was a good, loving, and based on truth faith, people would accept love without being forced.

  • Bruce Saltzman - 4 days ago

    An initial trial of a malaria vaccine using chemically weakened cells from the parasite which is transmitted by mosquitoes has given volunteers 100% protection against the disease, if given at a high dose.
    In a trial, 67 volunteers received a placebo or low, medium or high doses of a drug called PfSPZ-CVac. They were then exposed to the early form of the malaria parasite, cells called sporozoites, between eight and 10 weeks after receiving the vaccination.
    More from IBTimes UK
    Malaria vaccine created from GM mosquitoes passes first human trial with strong results
    Patients who resist malaria infection boost hopes of finding new treatments
    Experimental malaria vaccine triggers long-term immune response in mice
    All of the people who had been given placebo and no dose of PfSPZ-CVac developed malarial symptoms, for which they were then treated. In the low-dose group, six out of nine people developed symptoms. In the medium-dose group, three out of nine people developed symptoms and in the high-dose group, none of the study participants developed symptoms.
    The participants tolerated the vaccine well, and there were no side effects reported compared with the placebo group. The 0.5ml vaccine fluid was administered by direct injection into a vein three times at four-week intervals.
    "By vaccinating with a live, fully active pathogen, it seems clear that we were able to set of a very strong immune response," said study author Benjamin Mordmueller of the University of Tuebingen, Germany, said in a statement.
    "Additionally, all the data we have so far indicate that what we have here is relatively stable, long-lasting protection."
    Last year Sanaria, the US-based biotech company developing the vaccine, published promising results with a serum called PfSPZ-Vaccine that weakened malaria sporozoites using radiation rather than chemicals. The chemical-based method could potentially convey high levels of protection at a lower cost, Stephen Hoffman, chief executive of Sanaria, told IBTimes UK.
    "The advantage we have here potentially with the chemical vaccination approach is that to get the same level of protection, it looks like one requires far fewer sporozoites," Hoffman said. "The cost of goods could be much less. Trials of PfSPZ-Vaccine are currently underway in Kenya, Tanzania and soon in Equatorial Guinea."

    Several candidates for a malaria vaccine being trialled. The RTS,S/ASO1 vaccine is the most advanced at present, says the World Health OrganizationTONY KARUMBA/AFP/Getty Images
    He continued: "It's possible that this [chemical] approach is better. It definitely is more potent on a sporozoite-per-sporozoite basis. That's a huge advantage, but the radiation-attenuated vaccine will probably be used too as part of multiple approaches.
    "The next steps for research on PfSPZ-CVac are to see how long the vaccine lasts, to test it in areas with natural exposure to malaria rather than in clinical conditions, and to test on multiple strains of the parasite."
    The vaccines are potential future preventatives in addition to RTS,S/ASO1, which is the most advanced candidate for a malarial vaccine so far, according to the World Health Organization (WHO). There were 212 million cases of malaria globally in 2015, leading to an estimated 429,000 malaria deaths, states the WHO.

  • William Wilhite - 5 days ago

    Possible black swans to wreck the market:
    Ukraine conflict escalates
    China builds a base on Scarborough Shoal
    China and Japan have a military encounter
    China yuan depreciates rapidily and deeply vs the dollar
    economy declines with social unrest
    Le Pen wins in France, leading to Frexit
    Grexit
    Euro collapses
    Fed rate hikes destroy the housing market
    inflation reduces actual spending due to lagging wages
    Trump administration collapses, leading to HUGE political turmoil
    North Korea launches an ICBM capable of striking the USA and then declares that to be its goal
    the rest of the USA hopes that North Korea does indeed hit California
    thus 2 birds with one stone

  • TERRY SMITH - 2 weeks ago

    unseen geopolitical events in mideast could seriously effect an already overpriced, and overconfident market..

Leave a Comment

0/4000 chars


Submit Comment